As of Jan 20
| +0.10 / +1.19%|
The 9 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 10.00. The median estimate represents a +29.41% increase from the last price of 8.50.
The current consensus among 10 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.